Anavar 20 (Oxandrolone 20mg) – 1181/12

Anavar 20 Oxandrolone (20mg)

ORAL USE / 100 Tablets

FORMULA
Each tablets contains:
Oxandrolone …………………. 20 mg
Excipients……………………. q.s.

Batch No: 1181/12

INDICATIONS

It is used in the treatment of catabolic processes or tissue reducers. Oxandrolone is indicated in conditions such as chronic infections, major surgery, (corticosteroid induced myopathy, decubitus ulcers, burns), or severe trauma, where it is required to stop the effects of catabolic processes or loss of
proteins. It is important to remember that this type of substances are adjuvants in these cases and do not replace conventional treatment of these disorders. It is also used for the treatment of Turner’s Syndrome, to treat short stature observed in these patients. However the theraphy is still controversial, reports on recent experiments show that Oxandrolone can be effective as a growth hormone and that it can increase the efficacy of growth hormone therapy. after 6 months of treatment.
 
MECHANISM OF ACTION
 
It reverses the catabolic processes and negative balance of nitrogen enhancing protein synthesis and stimulating the appetite if there is a simultaneous intake of calories and proteins. It is administrated orally, since oxandrolone presents a first half-life of 0,55 hours and another of 9 hours. It is eliminated through the kidneys and in small amounts in feces.
 
DOSAGE
 
In adults, 2 – 4 weeks of therapy are usually recommended. Doses in adults and adolescents, 2.5 mg twice or four times a day. Maximum dose is 20 mg a day. Doses in children are 0,25 mcg (0,25 mg/weight/day). In cases of Turner’s syndrome, the doses are 0,05 to 0.125 mg/weight/day. Patients should generally start and keep a minimum effective dose to minimize adverse effects.
 
CONTRAINDICATIONS
 
Anabolic steroids are normally used for the treatment of symptoms associated with osteoporosis. However, the long-term use is not recommended because of questionable effects of these agents and the risk of serious side effects does not justify the use. The use of anabolic steroids is not recommended in athletes.
 
ADVERSE EFFECTS
 
Virilization, acne, enlarged clitoris, hoarseness, menstrual irregularities, hair loss have been observed in women. In prepubertal men, acne, penis enlargement, increased frequency of erections, abnormal erections, abnormal hair growth have been observed. In postpubertal men, bladder irritability (frequent urge to urinate), chest pain, breast
enlargement, frequent erections have been observed. Less frequently cases of anemia, iron deficiency, loss of appetite, oedema, nausea, vomit, unusual bleeding have been observed. Hypercalcemia (depression, unusual tiredness), unusual darkening of skin. In elderly patients prostate carcinoma or prostate hypertrophy (difficulty or frequent urge to urinate) can be seen. In rare cases hepatic necrosis (black stools, headache, vomiting blood, bad breath), hepatic cancer (stomachache or abdominal pain, unexplained weight loss), hepatic
peliosis (dark urine, loss of appetite, red spots on the skin, mouth, nose, throat, fever, nausea, vomits) have been observed.
 
DRUG INTERACTIONS
 
The use of anabolic steroids with adenocorticosteroids, glycocorticosteroids, drugs or food that contain sodium can
increase the possibility of oedema. Concomitant use of oxandrolone with anticoagulants can increase the effect of the anticoagulant. Anabolic steroids can decrease the concentration of glucose, diabetic patients
should be monitored for probable symptoms of hypoglycemia and doses of hypoglycemic agents or insulin should be adjusted. Concomitant use of anabolic steroids with hepatotoxic drugs can increase the hepatotoxicity. Patients with hepatic disorders should be carefully monitored.
 
PRECAUTIONS AND WARNINGS
 
There are no studies with oxandrolone in mutagenicity in vitro or animals. Studies with animals that received 9 times t h e h uma n d o s e h a v e s h own t h a t Oxandrolone can cause embryotoxicity, fetotoxicity and infertility and increased masculinization. Therefore, it should not be used during pregnancy. It is not known whether it is excreted in human milk, but its use should be avoided while the woman is breastfeeding. Use with caution in children and adolescents because of an early closure of the epiphysis. Medication should be withdrawn if there are
no results after 6 months of treatment.
 
OVERDOSE
 
Overdose treatment is symptomatic and supportive. In case of overdose, treat the patient with emesis and gastric lavage. Hepatic function should be monitored, since hepatotoxicity is a serious adverse effect.